|
所属 |
附属病院 脳神経外科 |
職務経歴（学内） 【 表示 ／ 非表示 】
-
2023年04月-継続中
秋田大学 附属病院 脳神経外科 講師
-
2017年07月-2023年03月
秋田大学 大学院医学系研究科（医学専攻等） 医学専攻 機能展開医学系 助教
職務経歴（学外） 【 表示 ／ 非表示 】
-
2017年07月-継続中
秋田大学大学院 脳神経外科 助教
-
2015年11月-2017年06月
ハイデルベルク大学神経 神経病理学研究室 客員研究員
研究経歴 【 表示 ／ 非表示 】
-
IDH-wildtype gliomaにおける悪性化機構の解明
科学研究費補助金
研究期間：
2019年04月-継続中研究態様：個人研究
-
IDHミュータント神経膠腫の病理分類と 悪性度に関する研究
国際共同研究
研究期間：
2015年11月-2017年10月研究態様：国際共同研究
-
テモゾロミド耐性悪性グリオーマに対するインターフェロンβ，ベバシズマブ併用テモゾロミド療法におけるアミノ酸トレーサを用いた効果判定の重要性
科学研究費補助金
研究期間：
2011年04月-2015年03月研究態様：国内共同研究
研究等業績 【 表示 ／ 非表示 】
-
SHIMIZU Hiroaki, ONO Takahiro, ABE Takatsugu, HOKARI Masaaki, EGASHIRA Yusuke, SHIMONAGA Koji, KAWANISHI Masahiko, NOMURA Kyoko, TAKAHASHI Yusuke
Neurologia medico-chirurgica ( 一般社団法人 日本脳神経外科学会 ) advpub ( 0 ) 80 - 89 2023年 [査読有り]
研究論文（学術雑誌）
<p>Intracranial carotid artery dissection causing cerebral ischemia is a rare but important cause of cerebral infarction in children and adolescents. Although endovascular therapy has been reported to be effective, questions regarding the indications for intervention are yet to be addressed. Therefore, this study aimed to evaluate factors related to clinical outcomes through a nationwide survey. Overall, 35 neurosurgical centers reported patients within 2 weeks after ischemic onset due to intracranial carotid artery dissection causing cerebral ischemia treated between January 2015 and December 2020. Data on clinical and radiological findings were statistically analyzed. Twenty-eight patients met the inclusion criteria. The median age was 36 years (range, 7-59 years), without sex differences. Headache at onset was documented in 60.7% of the patients. Dissection findings were categorized into stenosis (71.4%) or occlusion (28.6%). Initial treatments, including various antithrombotic agent combinations in 23 (82.1%) patients, effectively improved or prevented aggravation in half of the patients. The patients with stenotic dissection were significantly more likely to experience aggravation during the initial treatment than did those with occlusive dissection (<i>P</i> = 0.03). In addition, the patients with moderate to severe neurological deficits on admission had poorer outcomes at discharge more frequently than did those with mild neurological deficits on admission. Eight patients undergoing endovascular therapy had no procedural complications or further aggravation after intervention. In conclusion, patients with intracranial carotid dissection causing cerebral ischemia who had a stenotic dissection were at risk of further aggravation, and endovascular therapy effectively improved or prevented aggravation.</p>
-
Takahiro Ono, Felix Hinz, Shogo Tanaka, Masataka Takahashi, Hiroshi Nanjo, Andreas von Deimling, Hiroaki Shimizu
Journal of Neurosurgery: Case Lessons ( Journal of Neurosurgery Publishing Group (JNSPG) ) 3 ( 14 ) 2022年04月 [査読有り]
研究論文（学術雑誌）
BACKGROUND
Recent studies report that cerebellar glioblastoma (GBM) is categorized into the RTK1 methylation class. GBM pediatric RTK (pedRTK) subtypes are distinct from those of adult GBM. We present a unique adult case of cerebellar GBM classified into the pedRTK subtype.
OBSERVATIONS
Magnetic resonance imaging revealed a homogeneous enhancing lesion in the right cerebellum in a 56-year-old woman presenting with ataxia and dizziness. Arterial spin labeling and angiographic findings and the intraoperative orange-colored tumor appearance were reminiscent of hemangioblastoma. She showed an atypical presentation in terms of high glucose metabolism. The histological diagnosis was high-grade glioma with differentiation similar to central nervous system neuroblastoma. The methylation class was GBM pedRTK1. Consistent with this classification, immunoexpression was positive for SOX10 and negative for ANKRD55. She underwent craniospinal radiotherapy (23.4 Gy) with a boost to the tumor bed (total 55.8 Gy). Twelve courses of temozolomide therapy were administered. There was no recurrence 18 months after surgery.
LESSONS
Radiological and intraoperative findings, such as hemangioblastoma and high glucose metabolism, were notable characteristics in the present case. Both glial and neuronal differentiation and SOX10 immunoexpression were presenting pathological features. Similar cerebellar GBMs might form a previously unestablished subtype. Establishing effective molecular diagnoses is important. -
Oligosarcomas, IDH-mutant are distinct and aggressive
Suwala A.K.
Acta Neuropathologica ( Acta Neuropathologica ) 143 ( 2 ) 263 - 281 2022年02月 [査読有り]
研究論文（学術雑誌）
Oligodendrogliomas are defined at the molecular level by the presence of an IDH mutation and codeletion of chromosomal arms 1p and 19q. In the past, case reports and small studies described gliomas with sarcomatous features arising from oligodendrogliomas, so called oligosarcomas. Here, we report a series of 24 IDH-mutant oligosarcomas from 23 patients forming a distinct methylation class. The tumors were recurrences from prior oligodendrogliomas or developed de novo. Precursor tumors of 12 oligosarcomas were histologically and molecularly indistinguishable from conventional oligodendrogliomas. Oligosarcoma tumor cells were embedded in a dense network of reticulin fibers, frequently showing p53 accumulation, positivity for SMA and CALD1, loss of OLIG2 and gain of H3K27 trimethylation (H3K27me3) as compared to primary lesions. In 5 oligosarcomas no 1p/19q codeletion was detectable, although it was present in the primary lesions. Copy number neutral LOH was determined as underlying mechanism. Oligosarcomas harbored an increased chromosomal copy number variation load with frequent CDKN2A/B deletions. Proteomic profiling demonstrated oligosarcomas to be highly distinct from conventional CNS WHO grade 3 oligodendrogliomas with consistent evidence for a smooth muscle differentiation. Expression of several tumor suppressors was reduced with NF1 being lost frequently. In contrast, oncogenic YAP1 was aberrantly overexpressed in oligosarcomas. Panel sequencing revealed mutations in NF1 and TP53 along with IDH1/2 and TERT promoter mutations. Survival of patients was significantly poorer for oligosarcomas as first recurrence than for grade 3 oligodendrogliomas as first recurrence. These results establish oligosarcomas as a distinct group of IDH-mutant gliomas differing from conventional oligodendrogliomas on the histologic, epigenetic, proteomic, molecular and clinical level. The diagnosis can be based on the combined presence of (a) sarcomatous histology, (b) IDH-mutation and (c) TERT promoter mutation and/or 1p/19q codeletion, or, in unresolved cases, on its characteristic DNA methylation profile.
-
Asano K.
Brain Tumor Pathology ( Brain Tumor Pathology ) 2022年 [査読有り]
研究論文（学術雑誌）
-
Suzuki H.
Journal of Neuro-Oncology ( Journal of Neuro-Oncology ) 159 ( 2 ) 397 - 408 2022年 [査読有り]
研究論文（学術雑誌）
PURPOSE: IDH-wildtype (IDHwt) diffuse gliomas are treated as glioblastoma, however, some of these may show less aggressive clinical courses. The authors investigated the clinical, histopathological, and molecular characteristics of such IDHwt indolent diffuse gliomas (iDGwt), which have not been well documented in the literature. METHODS: Adult patients with IDHwt gliomas admitted between 2011 and 2020 were surveyed. In this particular study, the clinical indolence was defined mainly as having a small enhancing lesion and a stable period for more than 1 month before surgery. The current WHO diagnostic criteria were adapted for the diagnoses. Gene mutations and copy number changes in 43 representative glioma-associated genes, MGMT promoter methylation status, and survival data were compared with those of The Cancer Genome Atlas reference cohort. RESULTS: Nine out of 180 surveyed cases (5.0%) fulfilled the present criteria of the iDGwt. Considering the representative regulatory pathways, 8 (88.9%), 4 (44.4%), and 1 (11.1%) case had genetic alterations in the PI3K/MAPK, TP53, and RB pathways, respectively. The frequency of the RB pathway alteration was significantly lower than that in the reference cohort (281 of 362 cases: 77.6%). Two cases (22.2%) showing EGFR amplification met the diagnostic criteria for glioblastoma, and the frequency was significantly lower than that in the reference cohort (412 of 426 cases: 96.7%). The overall survival (median: 37.5 months) in the present series was significantly longer than that in the reference cohort (n = 426, median: 13.9 months). CONCLUSIONS: iDGwt lacked the molecular features of glioblastoma except for the PI3K/MAPK pathway alteration.
-
内科医が知っておくべき脳出血の急性期治療
小野隆裕，清水宏明
Medicina ( 医学書院 ) 2016年02月
総説・解説（商業誌） 国内共著
-
間接血行再建術後に対側脳血流の改善がみられた成人もやもや病の1例
富樫 俊太郎, 木村 早希, 阿部 真道, 高橋 佑介, 小野 隆裕, 高橋 和孝, 清水 宏明
脳循環代謝 ( (一社)日本脳循環代謝学会 ) 34 ( 1 ) 140 - 140 2022年10月
-
R-IHCの自動化に向けて-病理医の立場から-
南條博, 廣嶋優子, 今井一博, 寺田かおり, 小野隆裕, 中村竜太, 大久保義真, 赤上陽一, 南谷佳弘
日本病理学会会誌 110 ( 1 ) 2021年
-
東北・新潟地区における高齢者悪性リンパ腫の臨床病理学的予後因子の検討-東北脳腫瘍研究会共同研究-
浅野研一郎, 山下洋二, 小野隆裕, 棗田学, 別府高明, 松田憲一朗, 市川優寛, 金森政之, 麓敏雄, 松坂方士, 黒瀬顕, 齋藤清, 園田順彦, 小笠原邦昭, 藤井幸彦, 清水宏明, 大熊洋揮, 北中千史, 嘉山孝正, 冨永悌二
Brain Tumor Pathology (Web) 38 ( Supplement ) 2021年
-
脳腫瘍術後てんかんの診断におけるarterial spin labelingの有用性
小野隆裕, 高橋和孝, 清水宏明
日本脳神経CI学会総会プログラム・抄録集(Web) 44th 2021年
-
視神経・視交叉に接触する非機能性下垂体腺腫に対する寡分割定位放射線治療の長期成績
畠愛子, 小田正哉, 高橋和孝, 小野隆裕, 清水宏明
日本脳神経CI学会総会プログラム・抄録集(Web) 44th 2021年
◆原著論文【 表示 ／ 非表示 】
◆総説・解説【 表示 ／ 非表示 】
◆その他【 表示 ／ 非表示 】
学術関係受賞 【 表示 ／ 非表示 】
-
第33回山下太郎学術研究奨励賞
2022年06月01日 一般財団法人山下太郎顕彰育英会 病理学および分子生物学的解析を統合した、悪性髄内腫瘍の診断の最適化
受賞者： 小野隆裕
科研費（文科省・学振）獲得実績 【 表示 ／ 非表示 】
-
IDH-wildtype gliomaにおける悪性化機構の解明
若手研究
研究期間: 2019年04月 - 2023年03月
-
IDH-wildtype gliomaにおける悪性化機構の解明
若手研究
研究期間: 2019年04月 - 2023年03月 代表者: 小野 隆裕